HANOI, VIETNAM - Media OutReach Neswire - 14 April 2025 - Together with world-renowned scientists including Prof. Joel F.

HANOI, VIETNAM / ACCESS Newswire / April 14, 2025 / Together with world-renowned scientists including Prof. Joel F. Habener, ...

Prof. Daniel Drucker’s pioneering work on GLP-1, in collaboration with world-renowned scientists, has transformed treatment for diabetes and obesity - and is now opening new frontiers in ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

How GLP-1 analogs are reshaping diabetes care and obesity treatment and unlocking potential in cardiovascular, inflammatory, ...

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk ...

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in ...

People taking an oral formulation of the glucagon-like peptide-1 (GLP-1) agonist semaglutide were 14% less likely than those taking a placebo to experience cardiovascular death, heart attack or stroke ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP ... We believe that Novo Nordisk’s expertise will play a key role in accelerating the global development of UBT251.” This ...

The addition of a candidate targeting glucagon, as well as GLP-1 and GIP ... We believe that Novo Nordisk's expertise will play a key role in accelerating the global development of UBT251." This ...